{ "schemaVersion": "deck-intelligence.v1", "id": "019dd923-5e88-73ef-bd5a-d62c891ad637", "slug": "d07ec288d5b21a01", "title": "2025 JP Morgan Healthcare Conference", "subtitle": "P&A Global", "author": "P&A Global", "pageCount": 3, "kind": "consulting-deck", "orientation": "portrait", "aspectRatio": 0.773, "document": { "id": "019dd923-5e88-73ef-bd5a-d62c891ad637", "slug": "d07ec288d5b21a01", "title": "2025 JP Morgan Healthcare Conference", "rawTitle": "2025 JP Morgan Healthcare Conference", "authorId": "JPMorgan", "authorName": "P&A Global", "authorDisplay": "P&A Global", "kind": { "slug": "consulting-deck", "label": "Consulting deck" }, "sourceType": { "slug": "equity_research", "label": "Equity research" }, "fileName": "2025 JP Morgan Healthcare Conference.pdf", "sourceUrl": "https://www.paglobal.us", "sourceDate": "2025-01-01 00:00:00", "presentationDate": null, "ingestedAt": "2026-04-24 14:50:31+00", "status": "ready", "pageCount": 3, "orientation": "portrait", "aspectRatio": 0.773, "targetCompany": null, "targetTicker": null, "metadata": { "local_root": "/tmp/legacy-images/d07ec288d5b21a01", "origin_corpus": "consulting" } }, "coverage": { "pageCount": 3, "pagesIndexed": 3, "pagesWithImages": 3, "pagesWithMetadata": 3, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 11, "chartCount": 0, "metricSlides": 0, "toolMatches": 2, "documentToolMatches": 0, "frameworkMatches": 0, "arcMatches": 1, "beatMatches": 2, "loopMatches": 0, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": true, "reviewAvailable": true, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null, "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "matchId": "a72293fa-392e-4057-b80e-a5b3bd5d5107", "evidence": "The deck seems to provide a brief overview and updates, fitting the Sparkline narrative shape.", "isPrimary": true, "confidence": 0.7, "extraction": { "at": "2026-07-16 21:21:08.378195+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 1, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null, "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "from": 1, "name": "Setup", "beatId": "643c71f0-37f5-4157-bc1e-96c93b70d255", "matchId": "a72293fa-392e-4057-b80e-a5b3bd5d5107", "beatType": { "name": "Setup", "slug": "setup", "status": "active", "canonId": "019dd9b8-020e-7505-af9b-d9b9a4679bcc", "version": 1, "description": "Where the deck grounds the reader before doing anything else. Almost every arc opens here." }, "evidence": "The executive summary likely sets up the context for the conference.", "position": 0, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.7 }, { "to": 3, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null, "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "from": 2, "name": "Evidence", "beatId": "99ad4a1b-6a50-4fae-935e-79e6d5c324e1", "matchId": "a72293fa-392e-4057-b80e-a5b3bd5d5107", "beatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "evidence": "The initiative lists provide evidence of industry updates and developments.", "position": 1, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.7 } ], "loops": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2c0965f1-4458-464e-861e-c6ed51baf5d1", "evidence": "Day 1 Presentation on achievements, financial performance, and future plans.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 21:52:03.285559+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "9e2dbbb9-2e02-443b-bf10-3a96fc59a946", "evidence": "list/bullet: 7. Pfizer: Reaffirmed revenue targets and highlighted the impact of the Inflation Reduction Act.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-16 21:52:03.348573+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 2, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "patterns": [] }, "storymakers": null, "score": { "backend": "codex", "scoredAt": "2026-05-02 14:21:20.583+00", "subScores": { "scqa_arc": 18, "action_titles": 12, "mece_structure": 35, "closing_strength": 10, "evidence_quality": 45, "clarity_of_thesis": 25, "production_quality": 38, "visual_storytelling": 30 }, "totalScore": 27, "coveragePct": 100, "explanations": { "scqa_arc": "Slides 1-3 read as an analytical briefing dump of conference updates, with no clear Situation-Complication-Question-Answer progression.", "action_titles": "Titles are mostly topic labels rather than insight-bearing claims, for example Slide 2 uses \"Industry Updates: Key Pharmaceutical Company Developments.\"", "mece_structure": "The deck appears organized as a sequential company-by-company list across Slides 1-3, which limits overlap but does not form a complete strategic issue tree or prioritized set of arguments.", "closing_strength": "The deck ends on Slide 3 with a continuation of company updates rather than a recommendation, decision, implication, or next-step call to action.", "evidence_quality": "Slides 2-3 include multiple data points and company milestones, but the brief suggests summarized assertions rather than visible charts, cited sources, or analytical proof.", "clarity_of_thesis": "The first three slides establish the conference context but do not state a declarative central argument or so-what, with Slide 1 titled only \"2025 J.P. Morgan Healthcare Conference.\"", "production_quality": "Production discipline is mixed because the deck has sparse or balanced layouts, but action-title density is low and Slide 3's brand-style title weakens narrative continuity.", "visual_storytelling": "The inventory shows mainly title-body-list layouts on Slides 1-3, with little evidence of charts, frameworks, callouts, or big-number emphasis matched to the key message." }, "slidesAnalyzed": 3 }, "review": { "backend": null, "verdict": "This is an internal list-dump briefing, not a Storymakers exemplar — it functions as raw notes rather than a narrative deck and would need to be entirely restructured around action titles and MECE pillars to qualify.", "reviewedAt": "2026-05-01 22:34:00.527+00", "slidesSeen": 3, "suggestions": [ "Replace topic titles with action titles stating the insight (e.g., 'Six pharma leaders are pivoting capital from primary care to oncology and obesity in 2025')", "Add an executive summary slide that leads with the thesis and 3 MECE pillars (e.g., Pipeline bets / Capital reallocation / Geographic shifts) before the company-by-company list", "Group the 22 company updates under those pillars rather than presenting them as a flat numbered list", "Add a closing 'So what for P&A clients' slide with explicit recommendations and next steps", "Use SCQA framing: Situation (industry baseline) → Complication (what changed at JPM 2025) → Question (where to allocate attention) → Answer (the pillars and recommended actions)" ], "closingScore": 15, "openingScore": 30, "topStrengths": [ "Dense factual coverage — slides 2 and 3 pack ~8 data points each, useful as raw reference material" ], "topWeaknesses": [ "No narrative arc: deck is a list continuation (items 7-8, 15-22) with no setup, tension, or resolution", "Titles are topic labels, not insights — slide 3's title is literally just 'P&A GLOBAL'", "No synthesis layer: 22+ company updates with no MECE grouping or 'so what' pillars", "No closing recommendation or call to action; deck ends mid-enumeration" ], "narrativeScore": 25, "pillarCritique": "There are no MECE pillars or section dividers — the deck is one continuous numbered list of company updates with no thematic grouping (e.g., by therapeutic area, growth stage, or strategic posture).", "closingCritique": "Slide 3 ends mid-list (items 15-22) with the title literally just being the firm name 'P&A GLOBAL' — no recommendation, no call to action, no memorable close. It is effectively an appendix dump masquerading as a closing slide.", "openingCritique": "Slide 1 is a generic conference summary title that establishes topic but not stakes or thesis; the reader has no idea what the answer or 'so what' is. There is no hook, no lead-with-the-answer pyramid, just a briefing label.", "extractionSeconds": 47.674, "narrativeCritique": "There is no story arc — the deck is a sequential list dump (items 7-8, then 15-22) with no Situation→Complication→Analysis→Resolution structure. The 3 visible slides are all 'establish_context' or list continuations, with no tension, synthesis, or resolution acts present.", "titleQualityScore": 20, "titleQualityCritique": "Titles are pure topic labels, not action titles: 'Industry Updates: Key Pharmaceutical Company Developments' (slide 2) describes contents but states no insight, and slide 3's title is just the firm brand 'P&A GLOBAL'. None convey a takeaway a reader could quote." }, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "title": "The slide acts as a summary of industry updates from a specific conference.", "function": "summarize", "imagePath": "https://imgproxy.kitesheet.com/zAfZp1L-6MSOYLL99iB7E5PCVLqfphiZZU6JDdvH0gs/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kMDdlYzI4OGQ1YjIxYTAxL3AwMDEuanBn", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 5, "textChars": 1662, "nDataPoints": 2, "notes": "The slide acts as a summary of industry updates from a specific conference.", "elementsJson": [ "numbered_list", "logo_grid" ], "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 17:57:20.189+00", "seconds": 3.599, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5e88-73ef-bd5a-d62c891ad637/1", "deck": "/decks/019dd923-5e88-73ef-bd5a-d62c891ad637", "deckAnchor": "/decks/019dd923-5e88-73ef-bd5a-d62c891ad637#slide-1", "deckJson": "/decks/019dd923-5e88-73ef-bd5a-d62c891ad637.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.15, "x": 0.03, "y": 0.02 }, "kind": "image", "text": "P&A Global Logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 17:57:20.189+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bd26ea90-60fd-4f34-9933-dda642005f25", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.75, "x": 0.148, "y": 0.27 }, "kind": "list", "text": "1. Alnylam Pharmaceuticals: Focused on RNAi technologies, Alnylam reported significant growth and pipeline advancements, including positive Phase III data for Amvuttra in treating ATTR-CM. The company aims for a 40% revenue CAGR through 2025 and plans to launch Amvuttra in the US, Japan, and Germany in 2025.\n2. BioMarin Pharmaceuticals: Celebrated revenue growth and outlined plans for expanding indications for Voxzogo and Palynziq. The company anticipates several top-line results in 2025 and aims to achieve large BioPharma peer profit margins by 2026.\n3. Bristol Myers Squibb: Highlighted double-digit sales growth and the success of new brands like Cobenfy. The company plans to focus on newer assets to counter the impact of generics and aims for significant cost savings and reinvestment in growth initiatives.\n4. Incyte: Reported revenue growth and regulatory submissions for several products. The company expects pivotal trial readouts and multiple product launches in 2025, positioning it for future growth.\n5. Moderna: Emphasized its mRNA platform and reported significant sales from Spikevax. The company anticipates regulatory approvals and late-stage pipeline milestones in 2025, including a new COVID-19 vaccine and a combination flu/COVID-19 vaccine.\n6. Neurocrine Biosciences: Focused on the success of Ingrezza and the recent launch of Crenessity. The company plans to invest heavily in RCD and aims to deliver a new medicine to the market every two years.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 17:57:20.189+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a39436ad-f268-4f30-833e-c9eeccd47f41", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.51, "x": 0.148, "y": 0.2 }, "kind": "paragraph", "text": "Overview of Large, Mid and Small Pharmaceutical Companies", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 17:57:20.189+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "13adf552-a020-4632-a61f-df3f284778a3", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.65, "x": 0.148, "y": 0.237 }, "kind": "paragraph", "text": "Day 1 Presentation on achievements, financial performance, and future plans.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 17:57:20.189+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d484e3c2-99d4-46b5-a8ea-f57176192161", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.41, "x": 0.148, "y": 0.163 }, "kind": "title", "text": "2025 J.P. Morgan Healthcare Conference", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 17:57:20.189+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1884fb77-632c-4397-8289-6d13bbb488b6", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2c0965f1-4458-464e-861e-c6ed51baf5d1", "evidence": "Day 1 Presentation on achievements, financial performance, and future plans.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 21:52:03.285559+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 1, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 1, "name": "Setup", "beatId": "643c71f0-37f5-4157-bc1e-96c93b70d255", "matchId": "a72293fa-392e-4057-b80e-a5b3bd5d5107", "beatType": { "name": "Setup", "slug": "setup", "status": "active", "canonId": "019dd9b8-020e-7505-af9b-d9b9a4679bcc", "version": 1, "description": "Where the deck grounds the reader before doing anything else. Almost every arc opens here." }, "evidence": "The executive summary likely sets up the context for the conference.", "position": 0, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.7 } ], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/I9a2Xy34KQHbF031gs3YDTVrK5buJ6DMGqDRkmilNrE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kMDdlYzI4OGQ1YjIxYTAxL3AwMDEuanBn", "imagePathAlt": "https://imgproxy.kitesheet.com/HvievmTSubrD8YhlXUHAqOMY8u1RABzFIHNz6SgcpSE/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kMDdlYzI4OGQ1YjIxYTAxL3AwMDEucG5n", "thumbSrcAlt": "https://imgproxy.kitesheet.com/RX9YxOg2NCeJ8_yIn-CcABvkFu5d3Mmn4Px9OCtABns/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kMDdlYzI4OGQ1YjIxYTAxL3AwMDEucG5n" }, { "page": 2, "type": "setup", "title": "This is a continuation of a list (starts at item 7).", "function": "summarize", "rawType": "initiative_list", "block": null, "metadata": { "slideType": "initiative_list", "slideTypeCanon": { "name": "Initiative list", "slug": "initiative_list", "status": "active", "canonId": "019de52d-0caf-770e-9b91-b99239121f50", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 39, "componentCount": 2, "textChars": 1675, "nDataPoints": 0, "notes": "This is a continuation of a list (starts at item 7).", "elementsJson": [ "numbered_list", "logo_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 17:57:20.728+00", "seconds": 4.091, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5e88-73ef-bd5a-d62c891ad637/2", "deck": "/decks/019dd923-5e88-73ef-bd5a-d62c891ad637", "deckAnchor": "/decks/019dd923-5e88-73ef-bd5a-d62c891ad637#slide-2", "deckJson": "/decks/019dd923-5e88-73ef-bd5a-d62c891ad637.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.17, "x": 0.03, "y": 0.02 }, "kind": "image", "text": "P&A Global", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 17:57:20.728+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4074f520-108a-4682-bbe5-5a994d475752", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.68, "x": 0.16, "y": 0.15 }, "kind": "list", "text": "7. Pfizer: Reaffirmed revenue targets and highlighted the impact of the Inflation Reduction Act. The company plans to focus on oncology growth through its acquisition of Seagen and expects regulatory decisions for key products in 2025.\n8. Sarepta Therapeutics: Reported strong revenue growth driven by ELEVIDYS and outlined plans for expanding its gene therapy and RNA-based platforms. The company aims for significant revenue growth and multiple data readouts in 2025.\n9. Teva Pharmaceutical: Highlighted consecutive revenue growth and its Pivot to Growth strategy. The company focuses on innovative medicines and biosimilars, with key drugs like Austedo and Ajovy showing significant growth.\n10. Vertex Pharmaceuticals: Focused on the approval of Alyftrek for cystic fibrosis and the development of suzetrigine for acute pain. The company plans to expand its renal franchise and manufacturing capacity for Casgevy.\n11. Ascendis Pharma: Emphasized rapid revenue growth and the success of Skytrofa and Yorvipaith. The company plans to expand its endocrinology portfolio and form significant partnerships.\n12. BridgeBio Pharma: Highlighted clinical progress and the commercial potential of Attruby for ATTR-CM. The company expects pivotal data readouts and regulatory submissions in 2025.\n13. Cytokinetics: Focused on the launch of aficamten and omecamtiv mecarbil for heart failure. The company aims to build relationships with payers and achieve market access for its products.\n14. Edgewise Therapeutics: Reported progress in its muscle disease and cardiovascular disease pipeline. The company anticipates multiple data readouts and regulatory submissions in 2025.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 17:57:20.728+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f0d0fda4-e938-41ca-b0c3-81b7313b7885", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "9e2dbbb9-2e02-443b-bf10-3a96fc59a946", "evidence": "list/bullet: 7. Pfizer: Reaffirmed revenue targets and highlighted the impact of the Inflation Reduction Act.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-16 21:52:03.348573+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 2, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 3, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 2, "name": "Evidence", "beatId": "99ad4a1b-6a50-4fae-935e-79e6d5c324e1", "matchId": "a72293fa-392e-4057-b80e-a5b3bd5d5107", "beatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "evidence": "The initiative lists provide evidence of industry updates and developments.", "position": 1, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.7 } ], "loops": [], "locked": true }, { "page": 3, "type": "setup", "title": "This appears to be a continuation slide (items 15-22) from a larger report.", "function": "summarize", "rawType": "initiative_list", "block": null, "metadata": { "slideType": "initiative_list", "slideTypeCanon": { "name": "Initiative list", "slug": "initiative_list", "status": "active", "canonId": "019de52d-0caf-770e-9b91-b99239121f50", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 47, "componentCount": 4, "textChars": 1710, "nDataPoints": 0, "notes": "This appears to be a continuation slide (items 15-22) from a larger report.", "elementsJson": [ "numbered_list", "logo_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 17:57:23.664+00", "seconds": 6.838, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5e88-73ef-bd5a-d62c891ad637/3", "deck": "/decks/019dd923-5e88-73ef-bd5a-d62c891ad637", "deckAnchor": "/decks/019dd923-5e88-73ef-bd5a-d62c891ad637#slide-3", "deckJson": "/decks/019dd923-5e88-73ef-bd5a-d62c891ad637.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.15, "x": 0.05, "y": 0.02 }, "kind": "image", "text": "P&A Global", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 17:57:23.664+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a93b2c0-f911-4f21-b509-9f6c921fdaa0", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.7, "x": 0.15, "y": 0.15 }, "kind": "list", "text": "15. Inspire Medical Systems: Highlighted revenue growth and the approval of the Inspire V neurostimulation system. The company plans to expand its sales territories and launch new products in 2025.\n16. Recursion Pharmaceuticals: Emphasized its OS platform and oncology portfolio. The company plans to maximize the return on its business combination with Exscientia and achieve multiple milestones in 2025.\n17. Roivant Sciences: Focused on the potential of IMVT-1402 and Brepocitinib. The company anticipates multiple registrational trials and a strong capital position to achieve its goals.\n18. SpringWorks Therapeutics: Highlighted the success of Ogsiveo and the development of mirdametinib. The company plans for international launches and additional trials in 2025.\n19. Viking Therapeutics: Focused on the development of VK2735 for obesity and VK2809 for NASH. The company plans to initiate a Phase III program and achieve significant clinical milestones in 2025.\n20. Xenon Pharmaceuticals: Emphasized the development of azetukalner for epilepsy and MDD. The company anticipates key data readouts and regulatory submissions in 2025.\n21. Intellia Therapeutics: Highlighted its focus on NTLA-2002 and Nex-z for HAE and ATTR. The company plans to complete enrollment for its Phase III programs and prepare for regulatory submissions.\n22. Nuvation Bio: Reported progress in its oncology pipeline, including the approval of Taletrectinib in China. The company anticipates a commercial launch in the US and further clinical advancements in 2025.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 17:57:23.664+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "96b1c207-49a1-4b0d-8364-22e0d05fc2db", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.5, "x": 0.25, "y": 0.95 }, "kind": "paragraph", "text": "Proficiency . Partnership. Strategy . Results\nwww.paglobal.us", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 17:57:23.664+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a779c1e-a85e-4c82-babc-1bfe5d65dfe6", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.2, "x": 0.75, "y": 0.03 }, "kind": "paragraph", "text": "+1 (210) 956 - 1505\n+1 (412) 606 - 4399\n400 E. Randolph Street Ste: 715-C\nChicago, IL 60601 U.S.A", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 17:57:23.664+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1b7e473c-b013-4a75-b2d4-b36a483972e8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 3, "arc": { "name": "The Sparkline", "slug": "sparkline", "status": "active", "bestFor": "Keynotes, TED-style talks", "canonId": "019dd956-606e-720c-905a-42607ac0bf50", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "What Is -> What Could Be -> What Is -> What Could Be -> New Bliss", "description": null, "familyLabel": null }, "from": 2, "name": "Evidence", "beatId": "99ad4a1b-6a50-4fae-935e-79e6d5c324e1", "matchId": "a72293fa-392e-4057-b80e-a5b3bd5d5107", "beatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "evidence": "The initiative lists provide evidence of industry updates and developments.", "position": 1, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.7 } ], "loops": [], "locked": true } ], "arcBeats": [ { "from": 1, "to": 1, "label": "Setup", "description": "The executive summary likely sets up the context for the conference." }, { "from": 2, "to": 3, "label": "Evidence", "description": "The initiative lists provide evidence of industry updates and developments." } ], "loops": [] }